Telomir Pharmaceuticals (TELO) said Friday it was able to stabilize both Silver(I) and the highly reactive Silver(II) in a biologically compatible form with its Telomir-1 compound.
The company said the Telomir-1 compound would help overcome hurdles in silver-based medical applications and open up new possibilities for advanced antimicrobial treatments, wound care, and infection-resistant medical coatings.
The silver-based medical treatments market is rapidly growing, with the silver wound dressings segment valued at $1.03 billion in 2024 and expected to reach $1.36 billion by 2030, the company said.
Additionally, the company added that the antimicrobial coatings market, which includes silver-infused medical devices, hospital surfaces, and implants, is projected to grow from $11.65 billion in 2024 to $33.7 billion by 2031.
Telomir said it is advancing research and development to explore clinical applications of stabilized Silver(II) complexed-Telomir-1 and is evaluating regulatory pathways to bring these innovations to market.
Shares of the company rose 5% in recent premarket trading.
Price: 4.40, Change: +0.22, Percent Change: +5.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。